Compare · ABT vs KRRO
ABT vs KRRO
Side-by-side comparison of Abbott Laboratories (ABT) and Korro Bio Inc. (KRRO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and KRRO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $158.63B, about 1026.0x KRRO ($154.6M).
- Over the past year, ABT is down 31.9% and KRRO is down 27.3% - KRRO leads by 4.6 points.
- KRRO has been more active in the news (7 items in the past 4 weeks vs 6 for ABT).
- Both have 25 recent analyst ratings on file.
- Company
- Abbott Laboratories
- Korro Bio Inc.
- Price
- $90.77-0.32%
- $10.81-0.05%
- Market cap
- $158.63B
- $154.6M
- 1M return
- +4.39%
- -15.51%
- 1Y return
- -31.94%
- -27.29%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 6
- 7
- Recent ratings
- 25
- 25
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
- Director Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)
Latest KRRO
- President and CEO Aiyar Ram sold $196,673 worth of shares (15,152 units at $12.98), decreasing direct ownership by 17% to 74,848 units (SEC Form 4) to satisfy withholding tax
- Director Formela Jean Francois sold $39,897 worth of shares (2,860 units at $13.95) as part of a pre-agreed trading plan (SEC Form 4)
- President and CEO Aiyar Ram was granted 50,000 shares, increasing direct ownership by 125% to 90,000 units (SEC Form 4)
- Korro to Present at the 2026 Jefferies Global Healthcare Conference
- Korro Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
- Citigroup initiated coverage on Korro Bio with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Korro Bio Inc.
- Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 424B3 filed by Korro Bio Inc.